{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:24:35Z","timestamp":1781148275950,"version":"3.54.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12640-021-00411-4","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T06:02:43Z","timestamp":1631080963000},"page":"2141-2153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Exploring the Role of Orexinergic Neurons in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"39","author":[{"given":"Sachin","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-7708","authenticated-orcid":false,"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Harassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Abdel-Daim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"411_CR1","doi-asserted-by":"publisher","unstructured":"Akpa B, Lee K (2020)\u00a0Update on novel medications to treat narcolepsy. Current Sleep Medicine Reports 1\u20139. https:\/\/doi.org\/10.1007\/s40675-020-00178-8","DOI":"10.1007\/s40675-020-00178-8"},{"key":"411_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2017.09.007","volume":"660","author":"MM Alizamini","year":"2017","unstructured":"Alizamini MM, Farzinpour Z, Ezzatpanah S, Haghparast A (2017) Role of intra-accumbal orexin receptors in the acquisition of morphine-induced conditioned place preference in the rats. Neurosci Lett 660:1\u20135","journal-title":"Neurosci Lett"},{"issue":"2","key":"411_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/bc.bc_42_19","volume":"6","author":"HM Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy HM, Abdulhadi MH, Hussien NR, Al-Niemi MS, Rasheed HA, Al-Gareeb AI (2020) Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review. Brain Circulation 6(2):70. https:\/\/doi.org\/10.4103\/bc.bc_42_19","journal-title":"Brain Circulation"},{"issue":"1\u20133","key":"411_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.regpep.2005.01.003","volume":"129","author":"AF Apelbaum","year":"2005","unstructured":"Apelbaum AF, Perrut A, Chaput M (2005) Orexin A effects on the olfactory bulb spontaneous activity and odor responsiveness in freely breathing rats. Regul Pept 129(1\u20133):49\u201361","journal-title":"Regul Pept"},{"issue":"6","key":"411_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548\u2013560. https:\/\/doi.org\/10.1001\/jama.2019.22360","journal-title":"JAMA"},{"issue":"10","key":"411_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.5665\/sleep.5040","volume":"38","author":"I Arnulf","year":"2015","unstructured":"Arnulf I, Neutel D, Herlin B, Golmard JL, Leu-Semenescu S, Cochen de Cock V, Vidailhet M (2015) Sleepiness in idiopathic REM sleep behavior disorder and Parkinson disease. Sleep 38(10):1529\u20131535. https:\/\/doi.org\/10.5665\/sleep.5040","journal-title":"Sleep"},{"issue":"18","key":"411_CR7","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1523\/JNEUROSCI.4385-14.2015","volume":"35","author":"C Baimel","year":"2015","unstructured":"Baimel C, Borgland SL (2015) Orexin signaling in the VTA gates morphine-induced synaptic plasticity. J Neurosci 35(18):7295\u20137303. https:\/\/doi.org\/10.1523\/JNEUROSCI.4385-14.2015","journal-title":"J Neurosci"},{"key":"411_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab012","author":"L Barateau","year":"2021","unstructured":"Barateau L, Jaussent I, Roeser J, Ciardiello C, Kilduff TS, Dauvilliers Y (2021) Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence. Sleep. https:\/\/doi.org\/10.1093\/sleep\/zsab012","journal-title":"Sleep"},{"issue":"1","key":"411_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-020-00226-x","volume":"10","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S (2021) Cross-talks among GBA mutations, glucocerebrosidase, and \u03b1-synuclein in GBA-associated Parkinson\u2019s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegen 10(1):1\u201313. https:\/\/doi.org\/10.1186\/s40035-020-00226-x","journal-title":"Translational Neurodegeneration"},{"issue":"1","key":"411_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ejn.12761","volume":"41","author":"M Bensaid","year":"2015","unstructured":"Bensaid M, Tand\u00e9 D, Fabre V, Michel PP, Hirsch EC, Fran\u00e7ois C (2015) Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated macaques. Eur J Neurosci 41(1):129\u2013136. https:\/\/doi.org\/10.1111\/ejn.12761","journal-title":"Eur J Neurosci"},{"issue":"5","key":"411_CR11","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/npp.2011.310","volume":"37","author":"P Bettica","year":"2012","unstructured":"Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ (2012) Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37(5):1224\u20131233. https:\/\/doi.org\/10.1038\/npp.2011.310","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"411_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151288","volume":"11","author":"K Boddum","year":"2016","unstructured":"Boddum K, Hansen MH, Jennum PJ, Kornum BR (2016) Cerebrospinal fluid hypocretin-1 (Orexin-A) level fluctuates with season and correlates with day length. PLoS One 11(3):e0151288. https:\/\/doi.org\/10.1371\/journal.pone.0151288","journal-title":"PLoS ONE"},{"key":"411_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/NSS.S41245","volume":"5","author":"A Bridoux","year":"2013","unstructured":"Bridoux A, Moutereau S, Covali-Noroc A, Margarit L, Palfi S, Nguyen JP, Lefaucheur JP, C\u00e9saro P, d\u2019Ortho MP, Drouot X (2013) Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson\u2019s disease. Nature and Science of Sleep 5:87. https:\/\/doi.org\/10.2147\/NSS.S41245","journal-title":"Nature and Science of Sleep"},{"issue":"1","key":"411_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1001\/jamaneurol.2017.3171","volume":"75","author":"F B\u00fcchele","year":"2018","unstructured":"B\u00fcchele F, Hackius M, Schreglmann SR, Omlor W, Werth E, Maric A, Imbach LL, H\u00e4gele-Link S, Waldvogel D, Baumann CR (2018) Sodium oxybate for excessive daytime sleepiness and sleep disturbance in Parkinson disease: a randomized clinical trial. JAMA Neurol 75(1):114\u2013118. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3171","journal-title":"JAMA Neurol"},{"issue":"7","key":"411_CR15","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cellsig.2015.03.027","volume":"27","author":"J Chen","year":"2015","unstructured":"Chen J, Zhang R, Chen X, Wang C, Cai X, Liu H, Jiang Y, Liu C, Bai B (2015) Heterodimerization of human orexin receptor 1 and kappa opioid receptor promotes protein kinase A\/cAMP-response element binding protein signaling via a G\u03b1s-mediated mechanism. Cell Signal 27(7):1426\u20131438. https:\/\/doi.org\/10.1016\/j.cellsig.2015.03.027","journal-title":"Cell Signal"},{"key":"411_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fphys.2017.00357","volume":"8","author":"S Chieffi","year":"2017","unstructured":"Chieffi S, Carotenuto M, Monda V, Valenzano A, Villano I, Precenzano F, Tafuri D, Salerno M, Filippi N, Nuccio F, Ruberto M (2017) Orexin system: the key for a healthy life. Front Physiol 8:357. https:\/\/doi.org\/10.3389\/fphys.2017.00357","journal-title":"Front Physiol"},{"issue":"1","key":"411_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep36039","volume":"6","author":"S Chowdhury","year":"2016","unstructured":"Chowdhury S, Yamanaka A (2016) Optogenetic activation of serotonergic terminals facilitates GABAergic inhibitory input to orexin\/hypocretin neurons. Sci Rep 6(1):1\u201311. https:\/\/doi.org\/10.1038\/srep36039","journal-title":"Sci Rep"},{"issue":"6","key":"411_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.sleep.2011.01.012","volume":"12","author":"MM Clegg-Kraynok","year":"2011","unstructured":"Clegg-Kraynok MM, McBean AL, Montgomery-Downs HE (2011) Sleep quality and characteristics of college students who use prescription psychostimulants nonmedically. Sleep Med 12(6):598\u2013602. https:\/\/doi.org\/10.1016\/j.sleep.2011.01.012","journal-title":"Sleep Med"},{"issue":"1","key":"411_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep16143","volume":"5","author":"S Cole","year":"2015","unstructured":"Cole S, Mayer HS, Petrovich GD (2015) Orexin\/hypocretin-1 receptor antagonism selectively reduces cue-induced feeding in sated rats and recruits medial prefrontal cortex and thalamus. Sci Rep 5(1):1\u201311. https:\/\/doi.org\/10.1038\/srep16143","journal-title":"Sci Rep"},{"key":"411_CR20","doi-asserted-by":"publisher","unstructured":"Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ (2016)\u00a0A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia.\u00a0Int J Neuropharmacol\u00a019(8). https:\/\/doi.org\/10.1093\/ijnp\/pyw022","DOI":"10.1093\/ijnp\/pyw022"},{"issue":"1\u20132","key":"411_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jns.2011.04.024","volume":"307","author":"CS Constantinescu","year":"2011","unstructured":"Constantinescu CS, Niepel G, Patterson M, Judd A, Braitch M, Fahey AJ, Harikrishnan S, Edwards LJ, Tench CR, Bennett GW, Ghatei M (2011) Orexin A (hypocretin-1) levels are not reduced while cocaine\/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepiness. J Neurol Sci 307(1\u20132):127\u2013131. https:\/\/doi.org\/10.1016\/j.jns.2011.04.024","journal-title":"J Neurol Sci"},{"key":"411_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3389\/fendo.2019.00709","volume":"10","author":"A Couvineau","year":"2019","unstructured":"Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV (2019) Orexins as novel therapeutic targets in inflammatory and neurodegenerative diseases. Front Endocrinol 10:709. https:\/\/doi.org\/10.3389\/fendo.2019.00709","journal-title":"Front Endocrinol"},{"key":"411_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12264-010-0410-9","volume":"26","author":"LB Cui","year":"2010","unstructured":"Cui LB, Li BW, Jin XH, Zhao L, Shi J (2010) Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson\u2019s disease. Neurosci Bill 26:381\u2013387. https:\/\/doi.org\/10.1007\/s12264-010-0410-9","journal-title":"Neurosci Bill"},{"key":"411_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fphar.2014.00016","volume":"5","author":"L De Lecea","year":"2014","unstructured":"De Lecea L, Huerta R (2014) Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol 5:16. https:\/\/doi.org\/10.3389\/fphar.2014.00016","journal-title":"Front Pharmacol"},{"key":"411_CR25","doi-asserted-by":"crossref","unstructured":"De Lecea L, Kilduff TS, Peyron C, Gao XB, Foye PE, Danielson PE, C Fukuhara, Battenberg\u00a0ELF,\u00a0Gautvik Bartlett VT (1998) F.2. and Frankel, W.N. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci 95(1): 322\u2013327","DOI":"10.1073\/pnas.95.1.322"},{"issue":"s1","key":"411_CR26","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"E Dorsey","year":"2018","unstructured":"Dorsey E, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. Journal of Parkinson\u2019s Disease 8(s1):S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"411_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nlm.2018.11.008","volume":"157","author":"CM Duffy","year":"2019","unstructured":"Duffy CM, Hofmeister JJ, Nixon JP, Butterick TA (2019) High fat diet increases cognitive decline and neuroinflammation in a model of orexin loss. Neurobiol Learn Mem 157:41\u201347. https:\/\/doi.org\/10.1016\/j.nlm.2018.11.008","journal-title":"Neurobiol Learn Mem"},{"issue":"8","key":"411_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.neuint.2013.09.022","volume":"63","author":"S Esmaeili-Mahani","year":"2013","unstructured":"Esmaeili-Mahani S, Vazifekhah S, Pasban-Aliabadi H, Abbasnejad M, Sheibani V (2013) Protective effect of orexin-A on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells. Neurochem Int 63(8):719\u2013725. https:\/\/doi.org\/10.1016\/j.neuint.2013.09.022","journal-title":"Neurochem Int"},{"key":"411_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fnins.2014.00008","volume":"8","author":"K Etori","year":"2014","unstructured":"Etori K, Saito Y, Tsujino N, Sakurai T (2014) Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep\/wakefulness states in mice. Front Neurosci 8:8. https:\/\/doi.org\/10.3389\/fnins.2014.00008","journal-title":"Front Neurosci"},{"issue":"2","key":"411_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/adb.12339","volume":"22","author":"CA Feillet","year":"2017","unstructured":"Feillet CA, Bainier C, Mateo M, Blancas-Vel\u00e1zquez A, Salaberry NL, Ripperger JA, Albrecht U, Mendoza J (2017) Rev-erb\u03b1 modulates the hypothalamic orexinergic system to influence pleasurable feeding behaviour in mice. Addict Biol 22(2):411\u2013422. https:\/\/doi.org\/10.1111\/adb.12339","journal-title":"Addict Biol"},{"key":"411_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neulet.2014.07.014","volume":"579","author":"Y Feng","year":"2014","unstructured":"Feng Y, Liu T, Li XQ, Liu Y, Zhu XY, Jankovic J, Pan TH, Wu YC (2014) Neuroprotection by Orexin-A via HIF-1\u03b1 induction in a cellular model of Parkinson\u2019s disease. Neurosci Lett 579:35\u201340. https:\/\/doi.org\/10.1016\/j.neulet.2014.07.014","journal-title":"Neurosci Lett"},{"issue":"3","key":"411_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.nbd.2011.10.019","volume":"46","author":"I Ferrer","year":"2012","unstructured":"Ferrer I, L\u00f3pez-Gonzalez I, Carmona M, Dalf\u00f3 E, Pujol A, Mart\u00ednez A (2012) Neurochemistry and the non-motor aspects of PD. Neurobiol Dis 46(3):508\u2013526. https:\/\/doi.org\/10.1016\/j.nbd.2011.10.019","journal-title":"Neurobiol Dis"},{"key":"411_CR33","doi-asserted-by":"publisher","unstructured":"Fronczek R, (2011)\u00a0The hypocretin system and sleepiness in Parkinson\u2019s disease. In Narcolepsy 347\u2013356. Springer, New York, NY. https:\/\/doi.org\/10.1007\/978-1-4419-8390-9_32","DOI":"10.1007\/978-1-4419-8390-9_32"},{"issue":"6","key":"411_CR34","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/brain\/awm090","volume":"130","author":"R Fronczek","year":"2007","unstructured":"Fronczek R, Overeem S, Lee SY, Hegeman IM, Van Pelt J, Van Duinen SG, Lammers GJ, Swaab DF (2007) Hypocretin (orexin) loss in Parkinson\u2019s disease. Brain 130(6):1577\u20131585","journal-title":"Brain"},{"issue":"8","key":"411_CR35","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.neurobiolaging.2011.03.014","volume":"33","author":"R Fronczek","year":"2012","unstructured":"Fronczek R, van Geest S, Fr\u00f6lich M, Overeem S, Roelandse FW, Lammers GJ, Swaab DF (2012) Hypocretin (orexin) loss in Alzheimer\u2019s disease. Neurobiol Aging 33(8):1642\u20131650","journal-title":"Neurobiol Aging"},{"issue":"5","key":"411_CR36","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10072-019-3708-z","volume":"40","author":"M Gencer","year":"2019","unstructured":"Gencer M, Akbay\u0131r E, \u015een M, Arsoy E, Y\u0131lmaz V, Bulut N, T\u00fcz\u00fcn E, T\u00fcrko\u011flu R (2019) Serum orexin-A levels are associated with disease progression and motor impairment in multiple sclerosis. Neurol Sci 40(5):1067\u20131070. https:\/\/doi.org\/10.1007\/s10072-019-3708-z","journal-title":"Neurol Sci"},{"issue":"5","key":"411_CR37","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/npp.2017.158","volume":"43","author":"TA Gentile","year":"2018","unstructured":"Gentile TA, Simmons SJ, Watson MN, Connelly KL, Brailoiu E, Zhang Y, Muschamp JW (2018) Effects of suvorexant, a dual orexin\/hypocretin receptor antagonist, on impulsive behavior associated with cocaine. Neuropsychopharmacology 43(5):1001\u20131009. https:\/\/doi.org\/10.1038\/npp.2017.158","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"411_CR38","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0014-4886(03)00388-1","volume":"184","author":"D Gerashchenko","year":"2003","unstructured":"Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, Mignot E, Shiromani PJ (2003) Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 184(2):1010\u20131016","journal-title":"Exp Neurol"},{"issue":"2","key":"411_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ene.12583","volume":"22","author":"AF Gigante","year":"2015","unstructured":"Gigante AF, Bruno G, Iliceto G, Guido M, Liuzzi D, Mancino PV, De Caro MF, Livrea P, Defazio G (2015) Action tremor in Parkinson\u2019s disease: frequency and relationship to motor and non-motor signs. Eur J Neurol 22(2):223\u2013228. https:\/\/doi.org\/10.1111\/ene.12583","journal-title":"Eur J Neurol"},{"key":"411_CR40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3389\/fneur.2018.00961","volume":"9","author":"MD Gjerstad","year":"2018","unstructured":"Gjerstad MD, Alves G, Maple-Gr\u00f8dem J (2018) Excessive daytime sleepiness and REM sleep behavior disorders in Parkinson\u2019s disease: a narrative review on early intervention with implications to neuroprotection. Front Neurol 9:961. https:\/\/doi.org\/10.3389\/fneur.2018.00961","journal-title":"Front Neurol"},{"issue":"9","key":"411_CR41","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.parkreldis.2013.05.006","volume":"19","author":"JG Goldman","year":"2013","unstructured":"Goldman JG, Ghode RA, Ouyang B, Bernard B, Goetz CG, Stebbins GT (2013) Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson\u2019s disease. Parkinsonism Relat Disord 19(9):806\u2013811. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.05.006","journal-title":"Parkinsonism Relat Disord"},{"key":"411_CR42","doi-asserted-by":"publisher","unstructured":"Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ (2012)\u00a0International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.\u00a0Pharmacol Rev\u00a064(3):389\u2013420. https:\/\/doi.org\/10.1124\/pr.111.005546","DOI":"10.1124\/pr.111.005546"},{"issue":"3","key":"411_CR43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1124\/mol.114.095703","volume":"87","author":"S Guerreiro","year":"2015","unstructured":"Guerreiro S, Florence C, Rousseau E, Hamadat S, Hirsch EC, Michel PP (2015) The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine. Mol Pharmacol 87(3):525\u2013532. https:\/\/doi.org\/10.1124\/mol.114.095703","journal-title":"Mol Pharmacol"},{"issue":"9","key":"411_CR44","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/01616412.2017.1352185","volume":"39","author":"Z Hadadianpour","year":"2017","unstructured":"Hadadianpour Z, Fatehi F, Ayoobi F, Kaeidi A, Shamsizadeh A, Fatemi I (2017) The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson\u2019s disease. Neurol Res 39(9):845\u2013851. https:\/\/doi.org\/10.1080\/01616412.2017.1352185","journal-title":"Neurol Res"},{"issue":"4","key":"411_CR45","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s11064-020-02957-9","volume":"45","author":"A Haghparast","year":"2020","unstructured":"Haghparast A, Matini T, Rezaee L, Rahban M, Tehranchi A, Haghparast A (2020) Involvement of orexinergic system within the nucleus accumbens in pain modulatory role of the lateral hypothalamus in orofacial pain model. Neurochem Res 45(4):851\u2013859. https:\/\/doi.org\/10.1007\/s11064-020-02957-9","journal-title":"Neurochem Res"},{"issue":"23","key":"411_CR46","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","volume":"79","author":"WJ Herring","year":"2012","unstructured":"Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D (2012) Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79(23):2265\u20132274. https:\/\/doi.org\/10.1212\/WNL.0b013e31827688ee","journal-title":"Neurology"},{"issue":"12","key":"411_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083029","volume":"8","author":"E Hrabovszky","year":"2013","unstructured":"Hrabovszky E, Moln\u00e1r CS, Borsay B\u00c1, Gergely P, Herczeg L, Liposits Z (2013) Orexinergic input to dopaminergic neurons of the human ventral tegmental area. PLoS One 8(12):e83029. https:\/\/doi.org\/10.1371\/journal.pone.0083029","journal-title":"PLoS ONE"},{"issue":"1","key":"411_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neurobiolaging.2014.08.010","volume":"36","author":"NJ Hunt","year":"2015","unstructured":"Hunt NJ, Rodriguez ML, Waters KA, Machaalani R (2015) Changes in orexin (hypocretin) neuronal expression with normal aging in the human hypothalamus. Neurobiol Aging 36(1):292\u2013300. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.08.010","journal-title":"Neurobiol Aging"},{"issue":"4","key":"411_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11906-017-0729-y","volume":"19","author":"R Imperatore","year":"2017","unstructured":"Imperatore R, Palomba L, Cristino L (2017) Role of orexin-A in hypertension and obesity. Curr Hypertens Rep 19(4):34. https:\/\/doi.org\/10.1007\/s11906-017-0729-y","journal-title":"Curr Hypertens Rep"},{"issue":"1\u20132","key":"411_CR50","first-page":"29","volume":"75","author":"A Inutsuka","year":"2013","unstructured":"Inutsuka A, Yamanaka A (2013) The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin\/hypocretin. Nagoya J Med Sci 75(1\u20132):29","journal-title":"Nagoya J Med Sci"},{"issue":"1\u20132","key":"411_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jns.2011.07.049","volume":"310","author":"A Iranzo","year":"2011","unstructured":"Iranzo A (2011) Sleep\u2013wake changes in the premotor stage of Parkinson disease. J Neurol Sci 310(1\u20132):283\u2013285. https:\/\/doi.org\/10.1016\/j.jns.2011.07.049","journal-title":"J Neurol Sci"},{"key":"411_CR52","doi-asserted-by":"publisher","unstructured":"Ishikawa T, Suzuki M, Kimura H (2020)\u00a00141 A novel, orally available orexin 2 receptor-selective agonist, TAK-994, shows wake-promoting effects following chronic dosing in an orexin-deficient narcolepsy mouse model. sleep 43:A56. https:\/\/doi.org\/10.1093\/sleep\/zsaa056.139","DOI":"10.1093\/sleep\/zsaa056.139"},{"issue":"3","key":"411_CR53","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4103\/2349-0977.201002","volume":"3","author":"S Jain","year":"2016","unstructured":"Jain S, Jain AK (2016) Orexin neuropetides: physiology and significance in food metabolism. Astrocyte 3(3):148. https:\/\/doi.org\/10.4103\/2349-0977.201002","journal-title":"Astrocyte"},{"key":"411_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.brainres.2011.03.045","volume":"1391","author":"B Jupp","year":"2011","unstructured":"Jupp B, Krivdic B, Krstew E, Lawrence AJ (2011) The orexin1 receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Res 1391:54\u201359. https:\/\/doi.org\/10.1016\/j.brainres.2011.03.045","journal-title":"Brain Res"},{"key":"411_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/B978-0-12-394623-2.00015-9","volume":"89","author":"H Katsuki","year":"2012","unstructured":"Katsuki H, Michinaga S (2012) Anti-Parkinson drugs and orexin neurons. Vitam Horm 89:279\u2013290. https:\/\/doi.org\/10.1016\/B978-0-12-394623-2.00015-9","journal-title":"Vitam Horm"},{"key":"411_CR56","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666200606233050","author":"G Kaur","year":"2020","unstructured":"Kaur G, Behl T, Bungau S, Kumar A, Uddin MS, Mehta V, Zengin G, Mathew B, Shah MA, Arora S (2020) Dysregulation of the gut-brain axis, dysbiosis and influence of numerous factors on gut microbiota associated Parkinson\u2019s disease. Curr Neuropharmacol. https:\/\/doi.org\/10.2174\/1570159X18666200606233050","journal-title":"Curr Neuropharmacol"},{"key":"411_CR57","doi-asserted-by":"publisher","unstructured":"Kim JS, Sung HY (2015)\u00a0Gastrointestinal autonomic dysfunction in patients with Parkinson\u2019s disease. Journal of movement disorders 8(2):76. https:\/\/doi.org\/10.14802\/jmd.15008","DOI":"10.14802\/jmd.15008"},{"key":"411_CR58","doi-asserted-by":"publisher","first-page":"A56","DOI":"10.1093\/sleep\/zsaa056.140","volume":"43","author":"H Kimura","year":"2020","unstructured":"Kimura H, Ishikawa T (2020) 0142 TAK-925, an orexin 2 receptor-selective agonist, enhanced cortical arousal in a narcolepsy mouse model different from effects of modafinil. Sleep 43:A56. https:\/\/doi.org\/10.1093\/sleep\/zsaa056.140","journal-title":"Sleep"},{"key":"411_CR59","doi-asserted-by":"publisher","unstructured":"Kukkonen JP (2016)\u00a0Orexin\/hypocretin signaling. Behavioral Neuroscience of Orexin\/Hypocretin 17\u201350. https:\/\/doi.org\/10.1007\/7854_2016_49","DOI":"10.1007\/7854_2016_49"},{"issue":"12","key":"411_CR60","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.parkreldis.2013.07.026","volume":"19","author":"Kurtis, M.M., Rodriguez-Blazquez, C., Martinez-Martin, P. and ELEP Group","year":"2013","unstructured":"Kurtis MM, Rodriguez-Blazquez C, Martinez-Martin P, ELEP Group (2013) Relationship between sleep disorders and other non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord 19(12):1152\u20131155. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.07.026","journal-title":"Parkinsonism Relat Disord"},{"key":"411_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fneur.2011.00026","volume":"2","author":"D La Herr\u00e1n-Arita","year":"2011","unstructured":"La Herr\u00e1n-Arita D, Alberto K, Guerra-Crespo M, Drucker-Colin R (2011) Narcolepsy and orexins: an example of progress in sleep research. Front Neurol 2:26. https:\/\/doi.org\/10.3389\/fneur.2011.00026","journal-title":"Front Neurol"},{"key":"411_CR62","unstructured":"Lassiter KR (2019)\u00a0Hormone signaling, gene expression, and mitochondrial hormone receptor expression in avian muscle (cells)"},{"issue":"2","key":"411_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.resp.2010.12.003","volume":"175","author":"RM Lazarenko","year":"2011","unstructured":"Lazarenko RM, Stornetta RL, Bayliss DA, Guyenet PG (2011) Orexin A activates retrotrapezoid neurons in mice. Respir Physiol Neurobiol 175(2):283\u2013287. https:\/\/doi.org\/10.1016\/j.resp.2010.12.003","journal-title":"Respir Physiol Neurobiol"},{"issue":"2","key":"411_CR64","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bph.12296","volume":"171","author":"CS Leonard","year":"2014","unstructured":"Leonard CS, Kukkonen JP (2014) Orexin\/hypocretin receptor signalling: a functional perspective. Br J Pharmacol 171(2):294\u2013313. https:\/\/doi.org\/10.1111\/bph.12296","journal-title":"Br J Pharmacol"},{"issue":"2","key":"411_CR65","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/rda.12478","volume":"50","author":"M Levanti","year":"2015","unstructured":"Levanti M, German\u00e0 A, Abbate F (2015) Orexin A expression in the ovary of dog and cat. Reprod Domest Anim 50(2):247\u2013250. https:\/\/doi.org\/10.1111\/rda.12478","journal-title":"Reprod Domest Anim"},{"issue":"5","key":"411_CR66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.smrv.2012.10.006","volume":"17","author":"MM Lima","year":"2013","unstructured":"Lima MM (2013) Sleep disturbances in Parkinson\u2019s disease: the contribution of dopamine in REM sleep regulation. Sleep Med Rev 17(5):367\u2013375. https:\/\/doi.org\/10.1016\/j.smrv.2012.10.006","journal-title":"Sleep Med Rev"},{"issue":"12","key":"411_CR67","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1111\/j.1460-9568.2012.08162.x","volume":"35","author":"HS Lindgren","year":"2012","unstructured":"Lindgren HS, Dunnett SB (2012) Cognitive dysfunction and depression in Parkinson\u2019s disease: what can be learned from rodent models? Eur J Neurosci 35(12):1894\u20131907. https:\/\/doi.org\/10.1111\/j.1460-9568.2012.08162.x","journal-title":"Eur J Neurosci"},{"issue":"1","key":"411_CR68","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1152\/ajpregu.00150.2018","volume":"316","author":"V Linehan","year":"2019","unstructured":"Linehan V, Rowe TM, Hirasawa M (2019) Dopamine modulates excitatory transmission to orexin neurons in a receptor subtype-specific manner. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 316(1):R68\u2013R75. https:\/\/doi.org\/10.1152\/ajpregu.00150.2018","journal-title":"American Journal of Physiology-Regulatory, Integrative and Comparative Physiology"},{"key":"411_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104754","volume":"138","author":"C Liu","year":"2020","unstructured":"Liu C, Xue Y, Liu MF, Wang Y, Chen L (2020) Orexin and Parkinson\u2019s disease: a protective neuropeptide with therapeutic potential. Neurochem Int 138:104754. https:\/\/doi.org\/10.1016\/j.neuint.2020.104754","journal-title":"Neurochem Int"},{"key":"411_CR70","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fnins.2018.00835","volume":"12","author":"MF Liu","year":"2018","unstructured":"Liu MF, Xue Y, Liu C, Liu YH, Diao HL, Wang Y, Pan YP, Chen L (2018) Orexin-A exerts neuroprotective effects via OX1R in Parkinson\u2019s disease. Front Neurosci 12:835. https:\/\/doi.org\/10.3389\/fnins.2018.00835","journal-title":"Front Neurosci"},{"issue":"7","key":"411_CR71","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1517\/14656566.2013.783021","volume":"14","author":"R Lopez","year":"2013","unstructured":"Lopez R, Dauvilliers Y (2013) Pharmacotherapy options for cataplexy. Expert Opin Pharmacother 14(7):895\u2013903. https:\/\/doi.org\/10.1517\/14656566.2013.783021","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"411_CR72","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1515\/bmc-2011-0066","volume":"3","author":"CJ Madden","year":"2012","unstructured":"Madden CJ, Tupone D, Morrison SF (2012) Orexin modulates brown adipose tissue thermogenesis. Biomol Concepts 3(4):381\u2013386","journal-title":"Biomol Concepts"},{"issue":"12","key":"411_CR73","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.5665\/sleep.2232","volume":"35","author":"GM Mang","year":"2012","unstructured":"Mang GM, D\u00fcrst T, B\u00fcrki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE (2012) The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 35(12):1625\u20131635. https:\/\/doi.org\/10.5665\/sleep.2232","journal-title":"Sleep"},{"key":"411_CR74","doi-asserted-by":"crossref","unstructured":"McDowell KA (2011)\u00a0The Cycad Hypothesis: Sleep alterations in a progressive, environmental neurotoxin-induced model of parkinsonism (Doctoral dissertation).","DOI":"10.1096\/fasebj.24.1_supplement.300.7"},{"issue":"21","key":"411_CR75","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1016\/j.bmcl.2012.08.109","volume":"22","author":"CJ McElhinny Jr","year":"2012","unstructured":"McElhinny CJ Jr, Lewin AH, Mascarella SW, Runyon S, Brieaddy L, Carroll FI (2012) Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible confounding effects on in vivo and in vitro studies. Bioorg Med Chem Lett 22(21):6661\u20136664. https:\/\/doi.org\/10.1016\/j.bmcl.2012.08.109","journal-title":"Bioorg Med Chem Lett"},{"key":"411_CR76","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fncir.2016.00066","volume":"10","author":"A Messina","year":"2016","unstructured":"Messina A, De Fusco C, Monda V, Esposito M, Moscatelli F, Valenzano A, Carotenuto M, Viggiano E, Chieffi S, De Luca V, Cibelli G (2016) Role of the orexin system on the hypothalamus-pituitary-thyroid axis. Frontiers in Neural Circuits 10:66","journal-title":"Frontiers in Neural Circuits"},{"key":"411_CR77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fphys.2017.00137","volume":"8","author":"G Messina","year":"2017","unstructured":"Messina G, Valenzano A, Moscatelli F, Salerno M, Lonigro A, Esposito T, Monda V, Corso G, Messina A, Viggiano A, Triggiani AI (2017) Role of autonomic nervous system and orexinergic system on adipose tissue. Front Physiol 8:137. https:\/\/doi.org\/10.3389\/fphys.2017.00137","journal-title":"Front Physiol"},{"issue":"2","key":"411_CR78","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40263-012-0036-8","volume":"27","author":"M Mieda","year":"2013","unstructured":"Mieda M, Sakurai T (2013) Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. CNS Drugs 27(2):83\u201390. https:\/\/doi.org\/10.1007\/s40263-012-0036-8","journal-title":"CNS Drugs"},{"key":"411_CR79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fnut.2020.00005","volume":"7","author":"K Miyano","year":"2020","unstructured":"Miyano K, Ohshima K, Suzuki N, Furuya S, Yoshida Y, Nonaka M, Higami Y, Yoshizawa K, Fujii H, Uezono Y (2020) Japanese herbal medicine Ninjinyoeito mediates its orexigenic properties partially by activating orexin 1 receptors. Front Nutr 7:5. https:\/\/doi.org\/10.3389\/fnut.2020.00005","journal-title":"Front Nutr"},{"key":"411_CR80","doi-asserted-by":"publisher","unstructured":"Nakamura M, Kanbayashi T, Sugiura T, Inoue Y (2011)\u00a0Relationship between clinical characteristics of narcolepsy and CSF orexin\u2010A levels. J Sleep Res\u00a020(1pt1):45\u201349. https:\/\/doi.org\/10.1111\/j.1365-2869.2010.00870.x","DOI":"10.1111\/j.1365-2869.2010.00870.x"},{"key":"411_CR81","doi-asserted-by":"publisher","unstructured":"Nishino S, Sakai N (2016)\u00a0Modulations of ventral tegmental area (VTA) dopaminergic neurons by hypocretins\/orexins: implications in vigilance and behavioral control. Dopamine and Sleep 65\u201389. https:\/\/doi.org\/10.1007\/978-3-319-46437-4_5","DOI":"10.1007\/978-3-319-46437-4_5"},{"issue":"2","key":"411_CR82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1642-431X(12)60082-5","volume":"12","author":"A Nitkiewicz","year":"2012","unstructured":"Nitkiewicz A, Smolinska N, Maleszka A, Kiezun M, Kaminski T (2012) Localization of orexin A and orexin B in the porcine uterus. Reprod Biol 12(2):135\u2013155. https:\/\/doi.org\/10.1016\/S1642-431X(12)60082-5","journal-title":"Reprod Biol"},{"key":"411_CR83","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.brainres.2018.02.024","volume":"1686","author":"T Okumura","year":"2018","unstructured":"Okumura T, Nozu T, Kumei S, Takakusaki K, Ohhira M (2018) Ghrelin acts centrally to induce an antinociceptive action during colonic distension through the orexinergic, dopaminergic and opioid systems in conscious rats. Brain Res 1686:48\u201354. https:\/\/doi.org\/10.1016\/j.brainres.2018.02.024","journal-title":"Brain Res"},{"key":"411_CR84","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.expneurol.2018.08.004","volume":"309","author":"LM Oliveira","year":"2018","unstructured":"Oliveira LM, Falquetto B, Moreira TS, Takakura AC (2018) Orexinergic neurons are involved in the chemosensory control of breathing during the dark phase in a Parkinson\u2019s disease model. Exp Neurol 309:107\u2013118. https:\/\/doi.org\/10.1016\/j.expneurol.2018.08.004","journal-title":"Exp Neurol"},{"key":"411_CR85","doi-asserted-by":"publisher","first-page":"113110","DOI":"10.1016\/j.expneurol.2019.113110","volume":"323","author":"LM Oliveira","year":"2019","unstructured":"Oliveira LM, Henrique E, Bustelli IB, Netto NFC, Moreira TS, Takakura AC, Caetano AL (2019) Depletion of hypothalamic hypocretin\/orexin neurons correlates with impaired memory in a Parkinson\u2019s disease animal model. Exp Neurol 323:113110\u2013113110. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113110","journal-title":"Exp Neurol"},{"issue":"1","key":"411_CR86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.pbb.2011.12.011","volume":"101","author":"AE Panhelainen","year":"2012","unstructured":"Panhelainen AE, Korpi ER (2012) Evidence for a role of inhibition of orexinergic neurons in the anxiolytic and sedative effects of diazepam: a c-Fos study. Pharmacol Biochem Behav 101(1):115\u2013124. https:\/\/doi.org\/10.1016\/j.pbb.2011.12.011","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"411_CR87","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/rej.2016.1836","volume":"20","author":"H Pasban-Aliabadi","year":"2017","unstructured":"Pasban-Aliabadi H, Esmaeili-Mahani S, Abbasnejad M (2017) Orexin-A protects human neuroblastoma SH-SY5Y cells against 6-hydroxydopamine-induced neurotoxicity: involvement of PKC and PI3K signaling pathways. Rejuvenation Res 20(2):125\u2013133. https:\/\/doi.org\/10.1089\/rej.2016.1836","journal-title":"Rejuvenation Res"},{"issue":"19","key":"411_CR88","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1007\/s00213-014-3520-7","volume":"231","author":"AX Patel","year":"2014","unstructured":"Patel AX, Miller SR, Nathan PJ, Kanakaraj P, Napolitano A, Lawrence P, Koch A, Bullmore ET (2014) Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans. Psychopharmacology 231(19):3817\u20133828. https:\/\/doi.org\/10.1007\/s00213-014-3520-7","journal-title":"Psychopharmacology"},{"key":"411_CR89","doi-asserted-by":"publisher","unstructured":"Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L (2018)\u00a0Cannabis sativa L. and nonpsychoactive cannabinoids: their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Res Int.\u00a0https:\/\/doi.org\/10.1155\/2018\/1691428","DOI":"10.1155\/2018\/1691428"},{"key":"411_CR90","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer RF (2016) Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord 22:S119\u2013S122. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.004","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"411_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson Disease Nature Reviews Disease Primers 3(1):1\u201321. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Parkinson Disease Nature Reviews Disease Primers"},{"key":"411_CR92","doi-asserted-by":"publisher","unstructured":"Pokusa M, Hajduchova D, Buday T, Kralova Trancikova A (2020)\u00a0Respiratory function and dysfunction in Parkinson-type neurodegeneration. Physiol Res\u00a069. https:\/\/doi.org\/10.33549\/physiolres.934405","DOI":"10.33549\/physiolres.934405"},{"issue":"11","key":"411_CR93","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1212\/WNL.0000000000001364","volume":"84","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Gagnon JF, Bertrand JA, Marchand DG, Montplaisir JY (2015) Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 84(11):1104\u20131113. https:\/\/doi.org\/10.1212\/WNL.0000000000001364","journal-title":"Neurology"},{"key":"411_CR94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.domaniend.2017.12.003","volume":"63","author":"E Pruszynska-Oszmalek","year":"2018","unstructured":"Pruszynska-Oszmalek E, Kolodziejski PA, Kaczmarek P, Sassek M, Szczepankiewicz D, Mikula R, Nowak KW (2018) Orexin A but not orexin B regulates lipid metabolism and leptin secretion in isolated porcine adipocytes. Domest Anim Endocrinol 63:59\u201368. https:\/\/doi.org\/10.1016\/j.domaniend.2017.12.003","journal-title":"Domest Anim Endocrinol"},{"key":"411_CR95","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.biopha.2017.03.053","volume":"90","author":"BM Razavi","year":"2017","unstructured":"Razavi BM, Hosseinzadeh H (2017) A review of the role of orexin system in pain modulation. Biomed Pharmacother 90:187\u2013193. https:\/\/doi.org\/10.1016\/j.biopha.2017.03.053","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"411_CR96","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.conb.2013.04.007","volume":"23","author":"T Sakurai","year":"2013","unstructured":"Sakurai T (2013) Orexin deficiency and narcolepsy. Curr Opin Neurobiol 23(5):760\u2013766","journal-title":"Curr Opin Neurobiol"},{"issue":"5","key":"411_CR97","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/j.orcp.2013.12.001","volume":"8","author":"T Sakurai","year":"2014","unstructured":"Sakurai T (2014) Roles of orexins in the regulation of body weight homeostasis. Obes Res Clin Pract 8(5):e414\u2013e420","journal-title":"Obes Res Clin Pract"},{"issue":"4","key":"411_CR98","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92(4):573\u2013585","journal-title":"Cell"},{"issue":"5","key":"411_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020360","volume":"6","author":"K Sasaki","year":"2011","unstructured":"Sasaki K, Suzuki M, Mieda M, Tsujino N, Roth B, Sakurai T (2011) Pharmacogenetic modulation of orexin neurons alters sleep\/wakefulness states in mice. PLoS One 6(5):e20360. https:\/\/doi.org\/10.1371\/journal.pone.0020360","journal-title":"PLoS ONE"},{"key":"411_CR100","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","volume":"51","author":"TE Scammell","year":"2011","unstructured":"Scammell TE, Winrow CJ (2011) Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 51:243\u2013266. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010510-100528","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7","key":"411_CR101","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AH Schapira","year":"2017","unstructured":"Schapira AH, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435. https:\/\/doi.org\/10.1038\/nrn.2017.62","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"411_CR102","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00213-010-2127-x","volume":"215","author":"JR Shoblock","year":"2011","unstructured":"Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, Morton K, Palmer J, Bonaventure P, Carruthers NI, Lovenberg TW, Boggs J (2011) Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology 215(1):191\u2013203. https:\/\/doi.org\/10.1007\/s00213-010-2127-x","journal-title":"Psychopharmacology"},{"issue":"11","key":"411_CR103","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0b013e31822e560e","volume":"77","author":"F Sixel-D\u00f6ring","year":"2011","unstructured":"Sixel-D\u00f6ring F, Trautmann E, Mollenhauer B, Trenkwalder C (2011) Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology 77(11):1048\u20131054. https:\/\/doi.org\/10.1212\/WNL.0b013e31822e560e","journal-title":"Neurology"},{"issue":"1","key":"411_CR104","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1369-1600.2010.00294.x","volume":"17","author":"KP Skibicka","year":"2012","unstructured":"Skibicka KP, Hansson C, Egecioglu E, Dickson SL (2012) Role of ghrelin in food reward: impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor gene expression. Addict Biol 17(1):95\u2013107. https:\/\/doi.org\/10.1111\/j.1369-1600.2010.00294.x","journal-title":"Addict Biol"},{"issue":"13","key":"411_CR105","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1113\/JP275866","volume":"596","author":"GM Souza","year":"2018","unstructured":"Souza GM, Kanbar R, Stornetta DS, Abbott SB, Stornetta RL, Guyenet PG (2018) Breathing regulation and blood gas homeostasis after near complete lesions of the retrotrapezoid nucleus in adult rats. J Physiol 596(13):2521\u20132545. https:\/\/doi.org\/10.1113\/JP275866","journal-title":"J Physiol"},{"key":"411_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2018.11.032","volume":"1731","author":"S Soya","year":"2020","unstructured":"Soya S, Sakurai T (2020) Orexin as a modulator of fear-related behavior: hypothalamic control of noradrenaline circuit. Brain Res 1731:146037. https:\/\/doi.org\/10.1016\/j.brainres.2018.11.032","journal-title":"Brain Res"},{"issue":"9","key":"411_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044726","volume":"7","author":"S Srinivasan","year":"2012","unstructured":"Srinivasan S, Simms JA, Nielsen CK, Lieske SP, Bito-Onon JJ, Yi H, Hopf FW, Bonci A, Bartlett SE (2012) The dual orexin\/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. PLoS One 7(9):e44726. https:\/\/doi.org\/10.1371\/journal.pone.0044726","journal-title":"PLoS ONE"},{"issue":"1","key":"411_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13041-019-0514-8","volume":"12","author":"M Stanojlovic","year":"2019","unstructured":"Stanojlovic M, Pallais JP, Lee MK, Kotz CM (2019) Pharmacological and chemogenetic orexin\/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson\u2019s disease. Mol Brain 12(1):1\u201316. https:\/\/doi.org\/10.1186\/s13041-019-0514-8","journal-title":"Mol Brain"},{"issue":"8","key":"411_CR109","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1007\/s00429-015-1143-3","volume":"221","author":"RL Stornetta","year":"2016","unstructured":"Stornetta RL, Inglis MA, Viar KE, Guyenet PG (2016) Afferent and efferent connections of C1 cells with spinal cord or hypothalamic projections in mice. Brain Struct Funct 221(8):4027\u20134044","journal-title":"Brain Struct Funct"},{"key":"411_CR110","doi-asserted-by":"crossref","unstructured":"Suzuki K, Miyamoto\u00a0M,  Miyamoto\u00a0T,  Iwanami\u00a0M,  Hirata\u00a0K (2011) Sleep disturbances associated with Parkinson\u2019s disease Parkinson\u2019s Disease","DOI":"10.5772\/21476"},{"issue":"6","key":"411_CR111","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/brain\/awm097","volume":"130","author":"TC Thannickal","year":"2007","unstructured":"Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson\u2019s disease. Brain 130(6):1586\u20131595","journal-title":"Brain"},{"issue":"2","key":"411_CR112","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.bbr.2010.09.028","volume":"217","author":"JL Thompson","year":"2011","unstructured":"Thompson JL, Borgland SL (2011) A role for hypocretin\/orexin in motivation. Behav Brain Res 217(2):446\u2013453. https:\/\/doi.org\/10.1016\/j.bbr.2010.09.028","journal-title":"Behav Brain Res"},{"key":"411_CR113","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fnins.2014.00057","volume":"8","author":"MD Thompson","year":"2014","unstructured":"Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP (2014) OX1 and OX2 orexin\/hypocretin receptor pharmacogenetics. Front Neurosci 8:57. https:\/\/doi.org\/10.3389\/fnins.2014.00057","journal-title":"Front Neurosci"},{"key":"411_CR114","doi-asserted-by":"publisher","unstructured":"Tripathi S, Jha SK (2019)\u00a0Sleep and appetitive conditioned memory. In Sleep, Memory and Synaptic Plasticity 227\u2013254. Springer, Singapore. https:\/\/doi.org\/10.1007\/978-981-13-2814-5_9","DOI":"10.1007\/978-981-13-2814-5_9"},{"key":"411_CR115","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fnbeh.2013.00028","volume":"7","author":"N Tsujino","year":"2013","unstructured":"Tsujino N, Sakurai T (2013) Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci 7:28","journal-title":"Front Behav Neurosci"},{"key":"411_CR116","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neuropharm.2019.02.012","volume":"149","author":"M Usui","year":"2019","unstructured":"Usui M, Kaneko K, Oi Y, Kobayashi M (2019) Orexin facilitates GABAergic IPSCs via postsynaptic OX1 receptors coupling to the intracellular PKC signalling cascade in the rat cerebral cortex. Neuropharmacology 149:97\u2013112. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.012","journal-title":"Neuropharmacology"},{"key":"411_CR117","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fnins.2014.00038","volume":"8","author":"T Verberne","year":"2014","unstructured":"Verberne T, Sabetghadam A, Korim W (2014) Neural pathways that control the glucose counterregulatory response. Front Neurosci 8:38. https:\/\/doi.org\/10.3389\/fnins.2014.00038","journal-title":"Front Neurosci"},{"key":"411_CR118","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fnbeh.2017.00010","volume":"11","author":"I Villano","year":"2017","unstructured":"Villano I, Messina A, Valenzano A, Moscatelli F, Esposito T, Monda V, Esposito M, Precenzano F, Carotenuto M, Viggiano A, Chieffi S (2017) Basal forebrain cholinergic system and orexin neurons: effects on attention. Front Behav Neurosci 11:10. https:\/\/doi.org\/10.3389\/fnbeh.2017.00010","journal-title":"Front Behav Neurosci"},{"key":"411_CR119","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fnmol.2018.00220","volume":"11","author":"C Wang","year":"2018","unstructured":"Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, Bai B, Chen J (2018) The orexin\/receptor system: molecular mechanism and therapeutic potential for neurological diseases. Front Mol Neurosci 11:220. https:\/\/doi.org\/10.3389\/fnmol.2018.00220","journal-title":"Front Mol Neurosci"},{"issue":"1\u20132","key":"411_CR120","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/01677063.2011.566953","volume":"25","author":"CJ Winrow","year":"2011","unstructured":"Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR (2011) Promotion of sleep by suvorexant\u2014a novel dual orexin receptor antagonist. J Neurogenet 25(1\u20132):52\u201361. https:\/\/doi.org\/10.3109\/01677063.2011.566953","journal-title":"J Neurogenet"},{"issue":"2","key":"411_CR121","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ygcen.2011.01.001","volume":"171","author":"KK Wong","year":"2011","unstructured":"Wong KK, Ng SY, Lee LT, Ng HK, Chow BK (2011) Orexins and their receptors from fish to mammals: a comparative approach. Gen Comp Endocrinol 171(2):124\u2013130. https:\/\/doi.org\/10.1016\/j.ygcen.2011.01.001","journal-title":"Gen Comp Endocrinol"},{"issue":"3","key":"411_CR122","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.npep.2012.02.001","volume":"46","author":"H Wu","year":"2012","unstructured":"Wu H, Xia FZ, Xu H, Zhai HL, Zhang MF, Zhang HX, Li YX, Li Y, Gu T, Ma LM, Lu YL (2012) Acute effects of different glycemic index diets on serum motilin, orexin and neuropeptide Y concentrations in healthy individuals. Neuropeptides 46(3):113\u2013118. https:\/\/doi.org\/10.1016\/j.npep.2012.02.001","journal-title":"Neuropeptides"},{"issue":"12","key":"411_CR123","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.cellsig.2013.07.025","volume":"25","author":"TR Xu","year":"2013","unstructured":"Xu TR, Yang Y, Ward R, Gao L, Liu Y (2013) Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cell Signal 25(12):2413\u20132423. https:\/\/doi.org\/10.1016\/j.cellsig.2013.07.025","journal-title":"Cell Signal"},{"issue":"1","key":"411_CR124","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1113\/jphysiol.2006.113217","volume":"574","author":"B Xue","year":"2006","unstructured":"Xue B, Kahn BB (2006) AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 574(1):73\u201383","journal-title":"J Physiol"},{"key":"411_CR125","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fnins.2019.00195","volume":"13","author":"YL Yang","year":"2019","unstructured":"Yang YL, Ran XR, Li Y, Zhou L, Zheng LF, Han Y, Cai QQ, Wang ZY, Zhu JX (2019) Expression of dopamine receptors in the lateral hypothalamic nucleus and their potential regulation of gastric motility in rats with lesions of bilateral substantia Nigra. Front Neurosci 13:195. https:\/\/doi.org\/10.3389\/fnins.2019.00195","journal-title":"Front Neurosci"},{"key":"411_CR126","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnins.2014.00036","volume":"8","author":"JW Yeoh","year":"2014","unstructured":"Yeoh JW, Campbell EJ, James MH, Graham BA, Dayas CV (2014) Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Front Neurosci 8:36. https:\/\/doi.org\/10.3389\/fnins.2014.00036","journal-title":"Front Neurosci"},{"key":"411_CR127","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.brainres.2011.09.006","volume":"1420","author":"LF Zheng","year":"2011","unstructured":"Zheng LF, Wang ZY, Li XF, Song J, Hong F, Lian H, Wang Q, Feng XY, Tang YY, Zhang Y, Zhu JX (2011) Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson\u2019s disease. Brain Res 1420:59\u201367. https:\/\/doi.org\/10.1016\/j.brainres.2011.09.006","journal-title":"Brain Res"},{"issue":"8","key":"411_CR128","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.5665\/sleep.6030","volume":"39","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Fenik P, Zhan G, Somach R, Xin R, Veasey S (2016) Intermittent short sleep results in lasting sleep wake disturbances and degeneration of locus coeruleus and orexinergic neurons. Sleep 39(8):1601\u20131611. https:\/\/doi.org\/10.5665\/sleep.6030","journal-title":"Sleep"},{"issue":"1","key":"411_CR129","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/adb.12298","volume":"22","author":"W Zuo","year":"2017","unstructured":"Zuo W, Fu R, Hopf FW, Xie G, Krnjevi\u0107 K, Li J, Ye JH (2017) Ethanol drives aversive conditioning through dopamine 1 receptor and glutamate receptor-mediated activation of lateral habenula neurons. Addict Biol 22(1):103\u2013116. https:\/\/doi.org\/10.1111\/adb.12298","journal-title":"Addict Biol"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-021-00411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12640-021-00411-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-021-00411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T12:34:18Z","timestamp":1638448458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12640-021-00411-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1007\/s12640-021-00411-4","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"31 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}